Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 49 to 56 of 56 entries
Sorted by: Best Match Show Resources per page
Evaluation of Hepatoprotective effects of different doses of Lyophilized Beetroot powder in albino rabbits.

Pakistan journal of pharmaceutical sciences

Sarfaraz S, Ikram R, Munawwar R, Fatima S, Anser H, Fatima M.
PMID: 34836860
Pak J Pharm Sci. 2021 Sep;34(5):1917-1922.

Beta vulgaris L. is a vegetable most commonly consumed in salads and has been shown to possess multiple benefits. This research was carried out to observe the effects of Beta vulgaris powder at different doses orally in albino rabbits...

Cite
Sarfaraz S, Ikram R, Munawwar R, et al. Evaluation of Hepatoprotective effects of different doses of Lyophilized Beetroot powder in albino rabbits. Pak J Pharm Sci. 2021;34(5):1917-1922
Sarfaraz, S., Ikram, R., Munawwar, R., Fatima, S., Anser, H., & Fatima, M. (2021). Evaluation of Hepatoprotective effects of different doses of Lyophilized Beetroot powder in albino rabbits. Pakistan journal of pharmaceutical sciences, 34(5), 1917-1922.
Sarfaraz, Sana, et al. "Evaluation of Hepatoprotective effects of different doses of Lyophilized Beetroot powder in albino rabbits." Pakistan journal of pharmaceutical sciences vol. 34,5 (2021): 1917-1922.
Sarfaraz S, Ikram R, Munawwar R, Fatima S, Anser H, Fatima M. Evaluation of Hepatoprotective effects of different doses of Lyophilized Beetroot powder in albino rabbits. Pak J Pharm Sci. 2021 Sep;34(5):1917-1922. PMID: 34836860.
Copy Download .nbib Format: NLM
Adenoviral Vectors for Hemophilia Gene Therapy.

Journal of genetic syndromes & gene therapy

Brunetti-Pierri N, Ng P.
PMID: 24883229
J Genet Syndr Gene Ther. 2013 Apr 30;2:017.

Hemophilia is an inherited blood clotting disorder resulting from deficiency of blood coagulation factors. Current standard of care for hemophilia patients is frequent intravenous infusions of the missing coagulation factor. Gene therapy for hemophilia involves the introduction of a...

Cite
Brunetti-Pierri N, Ng P. Adenoviral Vectors for Hemophilia Gene Therapy. J Genet Syndr Gene Ther. 2013;2:017
Brunetti-Pierri, N., & Ng, P. (2013). Adenoviral Vectors for Hemophilia Gene Therapy. Journal of genetic syndromes & gene therapy, 2017.
Brunetti-Pierri, N, and Ng, Philip. "Adenoviral Vectors for Hemophilia Gene Therapy." Journal of genetic syndromes & gene therapy vol. 2 (2013): 017.
Brunetti-Pierri N, Ng P. Adenoviral Vectors for Hemophilia Gene Therapy. J Genet Syndr Gene Ther. 2013 Apr 30;2:017. PMID: 24883229; PMCID: PMC4039643.
Copy Download .nbib Format: NLM
Are hemostatic agents effective in the treatment of acute spontaneous intracerebral hemorrhage?.

Annals of emergency medicine

Worster A.
PMID: 20646786
Ann Emerg Med. 2011 Jan;57(1):66-7. doi: 10.1016/j.annemergmed.2010.05.022. Epub 2010 Jun 19.

UNLABELLED: MethodsDATA SOURCES: The investigators searched the Cochrane Stroke Group Trials and Central Register of Controlled Trials, MEDLINE (from 1966), EMBASE (from 1980), bibliographies of relevant articles, and clinical trial registries. Authors and pharmaceutical companies were contacted for clarification...

Cite
Worster A. Are hemostatic agents effective in the treatment of acute spontaneous intracerebral hemorrhage?. Ann Emerg Med. 2010;57(1):66-7doi: 10.1016/j.annemergmed.2010.05.022.
Worster, A. (2011). Are hemostatic agents effective in the treatment of acute spontaneous intracerebral hemorrhage?. Annals of emergency medicine, 57(1), 66-7. https://doi.org/10.1016/j.annemergmed.2010.05.022
Worster, Andrew. "Are hemostatic agents effective in the treatment of acute spontaneous intracerebral hemorrhage?." Annals of emergency medicine vol. 57,1 (2011): 66-7. doi: https://doi.org/10.1016/j.annemergmed.2010.05.022
Worster A. Are hemostatic agents effective in the treatment of acute spontaneous intracerebral hemorrhage?. Ann Emerg Med. 2011 Jan;57(1):66-7. doi: 10.1016/j.annemergmed.2010.05.022. Epub 2010 Jun 19. PMID: 20646786.
Copy Download .nbib Format: NLM
Hereditary thrombophilic risk factors for recurrent pregnancy loss.

Journal of community genetics

Bogdanova N, Markoff A.
PMID: 22460204
J Community Genet. 2010 Jun;1(2):47-53. doi: 10.1007/s12687-010-0011-3. Epub 2010 Jun 11.

This review summarizes current knowledge about the role of hereditary hypercoagulation factors predisposing to thrombophilia-associated recurrent fetal loss. Thrombophilias are a major cause of adverse pregnancy outcome, playing a role in the etiology of up to 40% of cases...

Cite
Bogdanova N, Markoff A. Hereditary thrombophilic risk factors for recurrent pregnancy loss. J Community Genet. 2010;1(2):47-53doi: 10.1007/s12687-010-0011-3.
Bogdanova, N., & Markoff, A. (2010). Hereditary thrombophilic risk factors for recurrent pregnancy loss. Journal of community genetics, 1(2), 47-53. https://doi.org/10.1007/s12687-010-0011-3
Bogdanova, Nadja, and Markoff, Arseni. "Hereditary thrombophilic risk factors for recurrent pregnancy loss." Journal of community genetics vol. 1,2 (2010): 47-53. doi: https://doi.org/10.1007/s12687-010-0011-3
Bogdanova N, Markoff A. Hereditary thrombophilic risk factors for recurrent pregnancy loss. J Community Genet. 2010 Jun;1(2):47-53. doi: 10.1007/s12687-010-0011-3. Epub 2010 Jun 11. PMID: 22460204; PMCID: PMC3185986.
Copy Download .nbib Format: NLM
Bone Density Status in Bleeding Disorders: Where Are We and What Needs to Be Done?.

Journal of bone metabolism

Mansouritorghabeh H, Rezaieyazdi Z.
PMID: 29259958
J Bone Metab. 2017 Nov;24(4):201-206. doi: 10.11005/jbm.2017.24.4.201. Epub 2017 Nov 30.

Bleeding disorders, including hemophilia, can be seen in every ethnic population in the world. Among various bleeding disorders, reduced bone density has been addressed in hemophilia A. In recent years, there has been an increasing interest in addressing osteopenia...

Cite
Mansouritorghabeh H, Rezaieyazdi Z. Bone Density Status in Bleeding Disorders: Where Are We and What Needs to Be Done?. J Bone Metab. 2017;24(4):201-206doi: 10.11005/jbm.2017.24.4.201.
Mansouritorghabeh, H., & Rezaieyazdi, Z. (2017). Bone Density Status in Bleeding Disorders: Where Are We and What Needs to Be Done?. Journal of bone metabolism, 24(4), 201-206. https://doi.org/10.11005/jbm.2017.24.4.201
Mansouritorghabeh, Hassan, and Rezaieyazdi, Zahra. "Bone Density Status in Bleeding Disorders: Where Are We and What Needs to Be Done?." Journal of bone metabolism vol. 24,4 (2017): 201-206. doi: https://doi.org/10.11005/jbm.2017.24.4.201
Mansouritorghabeh H, Rezaieyazdi Z. Bone Density Status in Bleeding Disorders: Where Are We and What Needs to Be Done?. J Bone Metab. 2017 Nov;24(4):201-206. doi: 10.11005/jbm.2017.24.4.201. Epub 2017 Nov 30. PMID: 29259958; PMCID: PMC5734944.
Copy Download .nbib Format: NLM
Successful synthesis of active human coagulation factor VII by co-expression of mammalian gamma-glutamyl carboxylase and modification of vit.K cycle in Drosophila Schneider S2 cells.

Cytotechnology

Nagahashi K, Umemura K, Kanayama N, Iwaki T.
PMID: 28070807
Cytotechnology. 2017 Apr;69(2):317-327. doi: 10.1007/s10616-016-0059-y. Epub 2017 Jan 09.

Mammalian gamma-glutamyl carboxylase and reduced vitamin K are indispensable for synthesis of mature mammalian vitamin K dependent proteins including some of blood coagulation factors (factors II, VII, IX, and X). It was well known that Drosophila melanogaster expressed gamma-glutamyl...

Cite
Nagahashi K, Umemura K, Kanayama N, et al. Successful synthesis of active human coagulation factor VII by co-expression of mammalian gamma-glutamyl carboxylase and modification of vit.K cycle in Drosophila Schneider S2 cells. Cytotechnology. 2017;69(2):317-327doi: 10.1007/s10616-016-0059-y.
Nagahashi, K., Umemura, K., Kanayama, N., & Iwaki, T. (2017). Successful synthesis of active human coagulation factor VII by co-expression of mammalian gamma-glutamyl carboxylase and modification of vit.K cycle in Drosophila Schneider S2 cells. Cytotechnology, 69(2), 317-327. https://doi.org/10.1007/s10616-016-0059-y
Nagahashi, Kotomi, et al. "Successful synthesis of active human coagulation factor VII by co-expression of mammalian gamma-glutamyl carboxylase and modification of vit.K cycle in Drosophila Schneider S2 cells." Cytotechnology vol. 69,2 (2017): 317-327. doi: https://doi.org/10.1007/s10616-016-0059-y
Nagahashi K, Umemura K, Kanayama N, Iwaki T. Successful synthesis of active human coagulation factor VII by co-expression of mammalian gamma-glutamyl carboxylase and modification of vit.K cycle in Drosophila Schneider S2 cells. Cytotechnology. 2017 Apr;69(2):317-327. doi: 10.1007/s10616-016-0059-y. Epub 2017 Jan 09. PMID: 28070807; PMCID: PMC5366968.
Copy Download .nbib Format: NLM
A Case of Traumatic Cerebrospinal Fluid Rhinorrhea Successfully Treated Using Intravenous Factor XIII Administration.

Cureus

Yasuda I, Katsuki M, Narita N.
PMID: 34306845
Cureus. 2021 Jun 14;13(6):e15633. doi: 10.7759/cureus.15633. eCollection 2021 Jun.

Traumatic cerebrospinal fluid (CSF) rhinorrhea occurs around 2% of severe head trauma. We should find the fistula and surgically seal it or perform conservative therapy with bed rest with/without lumbar spinal CSF drainage. However, the fistula may not be...

Cite
Yasuda I, Katsuki M, Narita N. A Case of Traumatic Cerebrospinal Fluid Rhinorrhea Successfully Treated Using Intravenous Factor XIII Administration. Cureus. 2021;13(6):e15633doi: 10.7759/cureus.15633.
Yasuda, I., Katsuki, M., & Narita, N. (2021). A Case of Traumatic Cerebrospinal Fluid Rhinorrhea Successfully Treated Using Intravenous Factor XIII Administration. Cureus, 13(6), e15633. https://doi.org/10.7759/cureus.15633
Yasuda, Iori, et al. "A Case of Traumatic Cerebrospinal Fluid Rhinorrhea Successfully Treated Using Intravenous Factor XIII Administration." Cureus vol. 13,6 (2021): e15633. doi: https://doi.org/10.7759/cureus.15633
Yasuda I, Katsuki M, Narita N. A Case of Traumatic Cerebrospinal Fluid Rhinorrhea Successfully Treated Using Intravenous Factor XIII Administration. Cureus. 2021 Jun 14;13(6):e15633. doi: 10.7759/cureus.15633. eCollection 2021 Jun. PMID: 34306845; PMCID: PMC8278359.
Copy Download .nbib Format: NLM
Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation.

Research and practice in thrombosis and haemostasis

Lu G, Lin J, Bui K, Curnutte JT, Conley PB.
PMID: 33313467
Res Pract Thromb Haemost. 2020 Aug 27;4(8):1282-1294. doi: 10.1002/rth2.12418. eCollection 2020 Nov.

BACKGROUND: Andexanet alfa (andexanet) is a modified human factor Xa (FXa) approved for anticoagulation reversal in patients with life-threatening bleeding treated with rivaroxaban or apixaban. Four-factor prothrombin complex concentrates (4F-PCCs) are approved for reversal of vitamin K antagonist-induced anticoagulation...

Cite
Lu G, Lin J, Bui K, et al. Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation. Res Pract Thromb Haemost. 2020;4(8):1282-1294doi: 10.1002/rth2.12418.
Lu, G., Lin, J., Bui, K., Curnutte, J. T., & Conley, P. B. (2020). Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation. Research and practice in thrombosis and haemostasis, 4(8), 1282-1294. https://doi.org/10.1002/rth2.12418
Lu, Genmin, et al. "Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation." Research and practice in thrombosis and haemostasis vol. 4,8 (2020): 1282-1294. doi: https://doi.org/10.1002/rth2.12418
Lu G, Lin J, Bui K, Curnutte JT, Conley PB. Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation. Res Pract Thromb Haemost. 2020 Aug 27;4(8):1282-1294. doi: 10.1002/rth2.12418. eCollection 2020 Nov. PMID: 33313467; PMCID: PMC7695565.
Copy Download .nbib Format: NLM
Showing 49 to 56 of 56 entries